Denikitug

DRUG3 trials

Sponsors

Gilead Sciences

Conditions

Advanced Microsatellite Stable Colorectal CancerAdvanced Solid TumorEsophageal AdenocarcinomaGastric AdenocarcinomaGastroesophageal JunctionHER2-negative

Phase 1

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

RecruitingNCT05007782

Gilead SciencesAdvanced Solid Tumor

Start: 2021-08-18End: 2028-12-31Target: 416Updated: 2025-12-29

Phase 2

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Not yet recruitingNCT07527858

Gilead SciencesAdvanced Microsatellite Stable Colorectal Cancer

Start: 2026-04-01End: 2028-12-01Target: 170Updated: 2026-04-14

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

RecruitingNCT07546812

Gilead SciencesEsophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction +1

Start: 2026-05-01End: 2030-01-01Target: 120Updated: 2026-05-18

Related Papers

Abstract CT232: Preliminary results of a phase 1, first-in-human, dose-escalation study of the anti-CCR8 antibody denikitug in participants with advanced solid tumors

Cancer Research2026-04-17